GB807826A - Derivatives of pyrimido[5,4-d] pyrimidine and production thereof - Google Patents
Derivatives of pyrimido[5,4-d] pyrimidine and production thereofInfo
- Publication number
- GB807826A GB807826A GB8017/56A GB801756A GB807826A GB 807826 A GB807826 A GB 807826A GB 8017/56 A GB8017/56 A GB 8017/56A GB 801756 A GB801756 A GB 801756A GB 807826 A GB807826 A GB 807826A
- Authority
- GB
- United Kingdom
- Prior art keywords
- bis
- pyrimidopyrimidine
- reacted
- morpholino
- heated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention comprises pyrimido [5,4-d] pyrimidines substituted in at least one of the 2-, 4-, 6- and 8-positions by one or more of the following atoms or groups: halogen (e.g. Cl, Br, I), amino, mono- or di-substituted amino (e.g. mono- or di-alkyl- or -aryl-amino), ether (e.g. alkoxy, aryloxy), thiol, thioether (e.g. alkylmercapto, carboxyalkylmercapto, arylmercapto), hydrazino, guanidino or heterocyclic groups, which groups may in turn be substituted; and the preparation of pyrimido [5,4-d] pyrimidine derivatives by reacting compounds of the general formula <FORM:0807826/IV (b)/1> (wherein at least one of the symbols R1-R4, which may be the same or different, represents a halogen atom and the remainder hydrogen, a substituted hydroxy group, an amino or thiol group or the residue of a heterocyclic ring) with compounds of the general formula H-R or MeI-R (wherein R represents bromine, iodine, a substituted hydroxy group, a free or substituted amino, thiol, guanidino or hydrazino group or the residue of a heterocyclic ring, and MeI represents an alkali metal atom). The reaction is advantageously carried out at - 20 DEG to 250 DEG C. (if necessary under pressure) in an inert solvent and diluent and in the presence of an acid-binding agent (e.g. an alkali metal hydroxide or carbonate, a tertiary amine, or excess of the second reaction component when suitable) and/or a reaction accelerator (e.g. of the Friedel-Crafts type) and/or copper powder, copper salts or strong inorganic acids as catalysts. When the starting material has more than one halogen atom available for exchange, the reaction may be carried out stepwise. In some cases also, not only halogen but also other substituents (e.g. free or substituted hydroxy or amino groups) may be replaced by the residue R. Suitable reactants H-R and MeI-R are alcohols, phenols, mercaptans, thiophenols, alkali metal alcoholates, phenolates, hydrosulphides and thiophenolates, ammonia, primary and secondary amines, guanidines, hydrazines, aminoalcohols, morpholine, piperidine and sodium iodide. In examples: (1) 4:6:8-trichloropyrimidopyrimidine is reacted with 6 molecular proportions of sodium methoxide in methanol to produce 4:6:8-trimethoxypyrimidopyrimide; (2) tetrachloropyrimidopyrimidine is reacted in dioxan with 4 molecular proportions of ammonia and various amines to replace the chlorine atoms in the 4- and 8-positions by the residues of the amino compounds, viz. N-hydroxyethylanilino, morpholino, p-chloranilino, b -hydroxyethylamino, b -diethylaminoethylamino, methyldodecylamino, isoamylamino, benzylamino, p - dimethylaminoanilino, diallylamino, methylcyclohexylamino, b -chlorethylamino, butylethanolamino, benzylethanolamino, 2:3 - dihydroxypropylamino, amino and carbethoxymethylamino; (3) 2:4:6:8 - tetrachloropyrimidopyrimidine is boiled with sodium iodide in acetone to produce 2:6-dichloro - 4:8 - diiodopyrimidopyrimidine; (4) the product of (3) is reacted with 4 molecular proportions of aniline in dioxan and benzene to form 2:6 - dichloro - 4:8 - dianilinopyrimidopyrimidine; (5) 2:4:6:8 - tetrachloropyrimidopyrimidine is refluxed with excess of aniline to give 2:4:6:8 - tetra-anilinopyrimidopyrimidine; the starting material may be replaced by 2:6-dichloro-4:8-dianilino-, -diamino-, -dihydroxy- or -dipiperidino-pyrimidopyrimidine; (6) 6-chloro-4:8-diiodopyrimidopyrimidine is reacted with 2.3-molecular proportions of morpholine and 2 molecular proportions of triethylamine in dioxan to produce 6 - chloro - 4:8 - dimorpholinopyrimidopyrimidine; (7) various 6-chloro-4:8-diaminopyrimidopyrimidines are heated (where necessary under pressure) with various amines to form 6 - morpholino - 4:8 - bis - (diethylamino) -, 6 - methylamino- and 6-morpholino-4:8-bis-(ethylamino) -, 6 - morpholino - 4:8 - di - (ethylethanolamino) -, 6 - anilino -, 6 - dimethylamino - and 6 - morpholino - 4:8 - diamino -, 6 - diethanolamino - 4:8 - bis - (allylamino) -, 6 - diethanolamino - 4:8 - dipiperidino -, 6 - (b - hydroxyethylamino) -, 6 - diisopropanolamino - and 6 - diethanolamino - 4:8 - dimorpholino -, 6 - methylethanolamino - 4:8 - bis - (methylamino) -, 6 - morpholino - 4:8 - di - (g - methoxypropylamino) -, 6 - diethanolamino - 4:8 - di - (p - nitroanilino) - and 6 - piperidino - 4:8 - di - (b - hydroxyethylamino) - pyrimidopyrimidine; (8) 2:4:6:8 - tetrachloropyrimidopyrimidine is reacted under vigorous conditions with excess of ammonia and various amines to replace all four chlorine atoms by dimethylamino, allylamino, methylethanolamino, b -hydroxyethylamino, piperidino, morpholino, p-chloranilino, amino and methylamino; (9) 4:6:8 - trichloropyrimidopyrimidine is reacted as in (2) to replace the chlorine atoms in the 4- and 8-positions by allylamino, methylethanolamino, diisopropylamino, methylamino, diethanolamino, p-nitroanilino, 3-methoxypropylamino, o-methoxyanilino, dibenzylamino, ethyleneimino and semicarbazido; (10) 2:6-dichloro - 4:8 - bis - (diethylamino) - pyrimidopyrimidine is refluxed with a solution of sodium in b -dimethylaminoethanol to produce 2:6-bis-(b - diethylaminoethoxy) - 4:8 - bis - (diethylamino) - pyrimidopyrimidine; (11) 4:6:8 - trichloro - 2 - thiopyrimidopyrimidine is reacted with 4 molecular proportions of morpholine in dioxan to form 6-chloro-2-thio-4:8-dimorpholinopyrimidopyrimidine; (12) piperidine similarly yields the corresponding dipiperidino compound; (13) 6 - methylthio - 2:4 - dichloropyrimidopyrimidine is reacted with excess of morpholine to produce 6-methylthio-2:4-dimorpholinopyrimidopyrimidine; (14) 2:6-dichloro - 4:8 - bis - (b - diethylaminoethylamino)-pyrimidopyrimidine is heated under pressure with sodium ethoxide in ethanol to replace the chlorine atoms by ethoxy groups; (15) 2:4:6:8-tetrachloropyrimidopyrimidine is heated with 4 molecular proportions of phenol and 2 of sodium carbonate to form 2:4:6:8-tetraphenoxypyrimidopyrimidine; (16) 2:4:6:8-tetrachloropyrimidopyrimidine is reacted with 4 molecular proportions each of thiophenol and sodium hydroxide in moist dioxan to give 2:4:6:8 - tetraphenylthiopyrimidopyrimidine; (17) 2:4:6:8-tetrachloropyrimidopyrimidine is refluxed with excess of sodium hydrosulphide in dimethylformamide to replace the chlorine atoms by thiol groups; (18) 2:4:6:8-tetrachloropyrimidopyrimidine is reacted with 6 molecular proportions of ethyl mercaptan and 2 of pyridine to produce 2:6-dichloro-4:8-diethylthiopyrimidopyrimidine; (19) 4:8 - dichloropyrimidopyrimidine is reacted as in (2) to replace the chlorine atoms by morpholino, piperidino, anilino, amino, methylamino, dimethylamino, hydrazino, N:N1-diphenylguanidino, b - hydroxyethylamino and N-hydroxyethyl - p - nitroanilino; (20) 4:8-dichloropyrimidopyrimidine is reacted with potassium hydrosulphide in alcohol and dioxan to produce 4:8-dithiopyrimidopyrimidine; (21) the product of (18) is heated under pressure with morpholine in aqueous copper sulphate solution to form 2:6-dimorpholino-4:8-diethylthiopyrimidopyrimidine; (22) 2:4:6:8 - tetrachloropyrimidopyrimidine is heated with excess of ethyl mercaptan and pyridine in dioxan to give 2:4:6:8 - tetraethylthiopyrimidopyrimidine; (23) 6 - chloro - 4:8 - di - (carboxymethylthio) - pyrimidopyrimidine is heated with morpholine to produce 6 - morpholino - 4:8 - di - (carboxymethylthio) - pyrimidopyrimidine; (24) 4:6:8-trichloropyrimidopyrimidine is heated under pressure with excess of thioglycollic acid and pyridine to produce 4:6:8-tri-(carboxymethylthio) - pyrimidopyrimidine; (25) 6-chloro-4:8-di - (propylamino) - pyrimidopyrimidine similarly yields 6-carboxymethylthio-4:8-di-(propylamino) - pyrimidopyrimidine; (26) various 2:6 - dichloro - 4:8 - diaminopyrimidopyrimidines are heated with various amines to form 2:6 - bis - (diethanolamino) - 4:8 - dipiperidino-, -4:8-bis-(diethylamino)-, -4:8-dipyrrolidino-, -4:8-bis-(diallylamino)-, -4:8-bis-(dimethylamino)-, -4:8-bis-(dibutylamino)- and -4:8-dimorpholino-, 2:6 - di - (methylethanolamino) - 4:8-dipiperidino- and -4:8-di-(dodecylethanolamino)-, 2:6 - di - (propylethanolamino) - 4:8 - dimorpholino-, and 2:6 - bis - (diisopropylamino) - 4:8 - dipiperidino - pyrimidopyrimidine; (27) similarly prepared, but at higher temperatures under pressure, are 2:6-dimorpholino - 4:8 - di - (ethylethanolamino) -, 4:8 - di - (propylethanolamino) -, - 4:8 - di - (methylethanolamino) -, - 4:8 - bis - (diethanolamino) - and - 4:8 - bis - (dimethylamino) -, 2:6 - dipiperidino - 4:8 - bis - (diethanolamino) -, - 4:8-bis - (isoamylamino) -, - 4:8 - dipyrrolidino - and -4:8-di-(benzylethanolamino)-, and 2:6-bis - (diethylamino) - 4:8 - bis - (diethanolamino) - pyrimidopyrimidine; (28) 2:4:6 - trichloropyrimidopyrimidine is heated (in some cases under pressure and in the presence of copper salts) with excess of various amines to replace all three chlorine atoms by methylamino, ethylamino, propylamino, dimethylamino, b -hydroxyethylamino, morpholino, anilino, p-chloroanilino and o-methoxyanilino; (29) 6 - chloro - 4:8 - dimorpholinopyrimidopyrimidine is heated (if desired under pressure) with various sodium alkoxide solutions to replace the chlorine atom by ethoxy, butoxy, b -diethylaminoethoxy, b -ethoxyethoxy and b -propoxyethoxy; (30) 2:6-dichloro-4:8-di-(b -propoxyethoxy) - pyrimidopyrimidine is heated with morpholine under pressure to give 2:6-dimorpholino - 4:8 - di - (b - propoxyethoxy) - pyrimidopyrimidine. Additional starting materials and products are listed. Starting materials. Halogen-substituted pyrimidopyrimidines are obtainable by (a) halogenation of the corresponding hydroxy compounds (e.g. the starting materials of Examples (1), (3), (5), (11), (13) and (19) are prepared by the action of PCl5 and/or POCl3 on, respectively, 4:6:8 - trihydroxy-, 3 - methyl - 2:6:8 - trihydroxy - 4 - oxo - 3:4 - dihydro -, 2:6 - dichloro - 4:8 - dihydroxy -, 4:6:8 - trihydroxy-2-thio-, 6-methylthio-2:4-dihydroxy-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE807826X | 1955-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB807826A true GB807826A (en) | 1959-01-21 |
Family
ID=6722936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8017/56A Expired GB807826A (en) | 1955-03-14 | 1956-03-14 | Derivatives of pyrimido[5,4-d] pyrimidine and production thereof |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB807826A (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
US3074928A (en) * | 1959-06-25 | 1963-01-22 | Thomae Gmbh Dr K | Basic-substituted pyrimido-[5,4-d]-pyrimidines |
US4478833A (en) * | 1980-12-27 | 1984-10-23 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Trisubstituted pyrimido[5,4-d]pyrimidines and salts thereof |
US4963541A (en) * | 1989-02-22 | 1990-10-16 | Abbott Laboratories | Pyrimido-pyrimidine lipoxygenase inhibiting compounds |
US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US6046216A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6156528A (en) * | 1997-05-30 | 2000-12-05 | Cell Pathways, Inc | Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia |
US6177471B1 (en) | 1999-01-29 | 2001-01-23 | Cell Pathways, Inc. | Method for treating patients with acne by administering a CGMP-specific PDE inhibitor |
US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6500610B1 (en) | 1997-05-30 | 2002-12-31 | Cell Pathways, Inc | Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
US7115647B2 (en) | 1998-01-14 | 2006-10-03 | Osi Pharmaceuticals, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
JP2007008929A (en) * | 2005-06-28 | 2007-01-18 | Samsung Electronics Co Ltd | Pyrimidopyrimidine derivative, organic thin film transistor using the same, and method for producing the same |
WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN118993902A (en) * | 2024-07-12 | 2024-11-22 | 波米科技有限公司 | Fluorenyl-containing crosslinking agent, preparation method and application |
-
1956
- 1956-03-14 GB GB8017/56A patent/GB807826A/en not_active Expired
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
US3074928A (en) * | 1959-06-25 | 1963-01-22 | Thomae Gmbh Dr K | Basic-substituted pyrimido-[5,4-d]-pyrimidines |
US4478833A (en) * | 1980-12-27 | 1984-10-23 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Trisubstituted pyrimido[5,4-d]pyrimidines and salts thereof |
US4963541A (en) * | 1989-02-22 | 1990-10-16 | Abbott Laboratories | Pyrimido-pyrimidine lipoxygenase inhibiting compounds |
US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US6046216A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
US6156528A (en) * | 1997-05-30 | 2000-12-05 | Cell Pathways, Inc | Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia |
US6500610B1 (en) | 1997-05-30 | 2002-12-31 | Cell Pathways, Inc | Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US7115647B2 (en) | 1998-01-14 | 2006-10-03 | Osi Pharmaceuticals, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
US6440981B1 (en) | 1998-09-11 | 2002-08-27 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6177471B1 (en) | 1999-01-29 | 2001-01-23 | Cell Pathways, Inc. | Method for treating patients with acne by administering a CGMP-specific PDE inhibitor |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
JP2007008929A (en) * | 2005-06-28 | 2007-01-18 | Samsung Electronics Co Ltd | Pyrimidopyrimidine derivative, organic thin film transistor using the same, and method for producing the same |
EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
EP4470609A2 (en) | 2019-01-18 | 2024-12-04 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN118993902A (en) * | 2024-07-12 | 2024-11-22 | 波米科技有限公司 | Fluorenyl-containing crosslinking agent, preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB807826A (en) | Derivatives of pyrimido[5,4-d] pyrimidine and production thereof | |
US3272811A (en) | Dihydrothieno-[3, 4-d]-pyrimidines | |
US2779780A (en) | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation | |
Koppel et al. | Pyrimidines. I. Synthesis of Pyrimidinethiols1, 2 | |
GB1077689A (en) | Derivatives of 3-methylpurine and methods of preparing the same | |
Robins | Potential Purine Antagonists. IX. Further Studies of Some 4, 6-Disubstituted Pyrazolo [3, 4-d] pyrimidines1 | |
Hendry et al. | 68. New cytotoxic agents with tumour-inhibitory activity. Part I. Some aziridinopyrimidine derivatives | |
Russell et al. | A Synthesis of 4-Amino-2-thiopyrimidines | |
US3113942A (en) | Mono-alkyl ethers of tris (2-hydroxyphenyl) triazines | |
US3082206A (en) | Novel 4-(p-aminobenzenesulphonamido)-2:6-diphenoxypyrimidines | |
US3498984A (en) | 4-amino-2-phenyl-6-thiopyrimidines | |
MONTGOMERY et al. | 7-Substituted 7H-Purines1 | |
GB699812A (en) | Manufacture of substituted pyrimidones | |
US3505331A (en) | Process for preparing 2,4-diamino-7-chloropyrido(2,3-d)pyrimidines | |
GB565501A (en) | Manufacture of para-amino-benzene-sulphonamido-pyrimidines | |
US3207756A (en) | Manufacture of herbicidal 2-methylthio-4, 6-bis-amino-s-triazine derivatives | |
Maggiolo | The Reaction of Thiocyanogen with Nitrogen Heterocycles; Pyridines, Pyrmidines and Quinolines1 | |
KR870011106A (en) | Method for preparing pyrimidine derivative | |
ROTH et al. | 5-Arylthiopyrimidines. II. 2-and 4-Alkylamino and 4-Amino Derivatives1 | |
Greenbaum et al. | 6-Uracilsulfonic Acid, a Sulronic Acid Analog of Orotic Acid1 | |
FI57400B (en) | PROCEDURE FOR FRAMSTAELLNING AV 2,4-DIAMINO-5-BENZYLPYRIMIDINE | |
GB1152883A (en) | 4,5-Polymethylene-Pyrimidine Derivatives | |
GB774095A (en) | Improvements in or relating to pyrimidine compounds | |
Makisumi | Synthesis of Potential Anticancer Agents. V. 6-Halo-s-triazolo [2, 3-a] pyrimidines. | |
GB1042295A (en) | Novel 4-sulfanilamido-pyrimidines and their salts and processes for the manufacture thereof |